Compare PBH & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | COGT |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2005 | 2018 |
| Metric | PBH | COGT |
|---|---|---|
| Price | $59.46 | $39.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $86.40 | $28.08 |
| AVG Volume (30 Days) | 454.8K | ★ 4.9M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.04 | N/A |
| Revenue | ★ $1,110,479,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.69 | N/A |
| P/E Ratio | $14.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $57.25 | $3.72 |
| 52 Week High | $90.04 | $41.27 |
| Indicator | PBH | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 87.20 |
| Support Level | $57.25 | $34.54 |
| Resistance Level | $60.35 | $36.29 |
| Average True Range (ATR) | 1.53 | 2.77 |
| MACD | 0.11 | 0.76 |
| Stochastic Oscillator | 53.58 | 95.40 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.